Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial

Anne Ségolène Cottereau, Annibale Versari, Annika Loft, Olivier Casasnovas, Monica Bellei, Romain Ricci, Stéphane Bardet, Antonio Castagnoli, Pauline Brice, John Raemaekers, Bénédicte Deau, Catherine Fortpied, Tiana Raveloarivahy, Emelie Van Zele, Loic Chartier, Thierry Vander Borght, Massimo Federico, Martin Hutchings, Umberto Ricardi, Marc AndreMichel Meignan

Research output: Contribution to journalArticle

Abstract

We tested baseline positron emission tomography (PET)/computed tomography (CT) as a measure of total tumor burden to better identify high-risk patients with early-stage Hodgkin lymphoma (HL). Patients with stage I-II HL enrolled in the standard arm (combined modality treatment) of the H10 trial (NCT00433433) with available baseline PET and interim PET (iPET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine were included. Total metabolic tumor volume (TMTV) was measured on baseline PET. iPET2 findings were reported negative (DS1-3) or positive (DS4-5) with the Deauville scale (DS). The prognostic value of TMTV was evaluated and compared with baseline characteristics, staging classifications, and iPET2. A total of 258 patients were eligible: 101 favorable and 157 unfavorable. The median follow-up was 55 months, with 27 progression-free survival (PFS) and 12 overall survival (OS) events. TMTV was a prognosticator of PFS (P < .0001) and OS (P 5 .0001), with 86% and 84% specificity, respectively. Five-year PFS and OS were 71% and 83% in the high-TMTV (>147 cm3) group (n 5 46), respectively, vs 92% and 98% in the low-TMTV group (£147 cm3). In multivariable analysis including iPET2, TMTV was the only baseline prognosticator compared with the current staging systems proposed by the European Organization for Research and Treatment of Cancer/Groupe d’Etude des Lymphomes de l’Adulte, German Hodgkin Study Group, or National Comprehensive Cancer Network. TMTV and iPET2 were independently prognostic and, combined, identified 4 risk groups: low (TMTV£1471DS1-3; 5-year PFS, 95%), low-intermediate (TMTV>1471DS1-3; 5-year PFS, 81.6%), high-intermediate (TMTV£1471DS4-5; 5-year PFS, 50%), and high (TMTV>1471DS4-5; 5-year PFS, 25%). TMTV improves baseline risk stratification of patients with early-stage HL compared with current staging systems and the predictive value of early PET response as well. (Blood. 2018;131(13):1456-1463)

Original languageEnglish
Pages (from-to)1456-1463
Number of pages8
JournalBlood
Volume131
Issue number13
DOIs
Publication statusPublished - Mar 29 2018

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial'. Together they form a unique fingerprint.

  • Cite this

    Cottereau, A. S., Versari, A., Loft, A., Casasnovas, O., Bellei, M., Ricci, R., Bardet, S., Castagnoli, A., Brice, P., Raemaekers, J., Deau, B., Fortpied, C., Raveloarivahy, T., Van Zele, E., Chartier, L., Borght, T. V., Federico, M., Hutchings, M., Ricardi, U., ... Meignan, M. (2018). Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood, 131(13), 1456-1463. https://doi.org/10.1182/blood-2017-07-795476